J 2020

Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile

JANSA, Pavel, Samuel HELLER, Michal SVOBODA, Michal PAD'OUR, David AMBROZ et. al.

Basic information

Original name

Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile

Authors

JANSA, Pavel (203 Czech Republic, guarantor), Samuel HELLER (203 Czech Republic), Michal SVOBODA (203 Czech Republic, belonging to the institution), Michal PAD'OUR (203 Czech Republic), David AMBROZ (203 Czech Republic), Vladimir DYTRYCH (203 Czech Republic), Michal SIRANEC (203 Czech Republic), Tomas KOVARNIK (203 Czech Republic), Marián FELŠŐCI (703 Slovakia, belonging to the institution), Martin HUTYRA, Ales LINHART (203 Czech Republic), Jaroslav LINDNER and Michael ASCHERMANN (203 Czech Republic)

Edition

Journal of Clinical Medicine, BASEL, MDPI, 2020, 2077-0383

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30218 General and internal medicine

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 4.241

RIV identification code

RIV/00216224:14110/20:00117462

Organization unit

Faculty of Medicine

DOI

UT WoS

000593224900001

Keywords in English

chronic thromboembolic pulmonary hypertension; balloon pulmonary angioplasty; efficacy; safety; quality of life; risk profile; survival

Tags

Tags

International impact, Reviewed
Změněno: 21/12/2020 08:43, Mgr. Tereza Miškechová

Abstract

V originále

Balloon pulmonary angioplasty (BPA) is a novel treatment option for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are not eligible for pulmonary endarterectomy (PEA) or suffer from persistent pulmonary hypertension after PEA. The aim of this study was to evaluate the real-life efficacy and safety of BPA in a consecutive group of patients who were diagnosed and treated in the national referral center for CTEPH in the Czech Republic. Here we report data from 160 BPA procedures performed in 64 patients. Efficacy analysis was performed in the subgroup of 25 patients who completed BPA series. Significant improvements were observed in New York Heart Association functional class (4% to 79% in I/II, p < 0.001), 6 min walking test distance (+54.3 m, p < 0.001), risk profile (15.8% to 68.5% with presence of 2/3 low risk criteria, p < 0.001), pulmonary artery mean pressure (-18%, p < 0.001), pulmonary vascular resistance (-32%, p < 0.001), stroke volume (+17%, p = 0.011) and quality of life (+37% in assessment of overall health status by a patient, p < 0.001). We observed 1 fatal periprocedural complication (1.6% of all 64 patients) and 19 BPA-related non-fatal complications (11.9% of all 160 interventions) that predominantly included hemoptysis (10.0% of all sessions). Overall survival at 12 months was 94.6%.